Severe asthma attack. Severe persistent asthma
Conditions
Interventions
Intervention 1: Intervention group: Intranasal Montelukast drug using Montelukast powder from Aldrich Company, carboxymethyl cellulose as a suspending agent, methylparaben and propylparaben as antimic
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 12 Years
Inclusion criteria
Inclusion criteria: Children 2 to 12 years old Hospitalization due to an acute asthma attack with a pulmonary index score (PIS) between 7 and 11 (moderate attack) or a score greater than 12 (severe attack)
Exclusion criteria
Exclusion criteria: Simultaneous treatment with systemic corticosteroids or antileukotrienes within 4 weeks before admission Other possible causes for the patient's symptoms such as pneumonia Having a history of chronic lung diseases and anatomical airway problems and congenital heart disease History of taking anticonvulsant and immunosuppressive drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of the asthma attack. Timepoint: On the first day of hospitalization, every 4 hours and on the following days of hospitalization, once a day, patients based on PIS score (pulmonary index score). Method of measurement: According to the reference, a moderate attack is defined based on the need for auxiliary oxygen-nebulizer albuterol and systemic glucocorticoid, and a severe attack is defined based on the need for auxiliary oxygen-nebulizer salbutamol and ipratropium-systemic glucocorticoid-magnesium sulfate. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Morteza Sadi Nejad
Esfahan University of Medical Sciences
Outcome results
None listed